vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and HCI Group, Inc. (HCI). Click either name above to swap in a different company.
HCI Group, Inc. is the larger business by last-quarter revenue ($246.2M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). HCI Group, Inc. runs the higher net margin — 39.7% vs -0.7%, a 40.4% gap on every dollar of revenue. On growth, HCI Group, Inc. posted the faster year-over-year revenue change (52.1% vs 0.7%). HCI Group, Inc. produced more free cash flow last quarter ($440.8M vs $21.3M). Over the past eight quarters, HCI Group, Inc.'s revenue compounded faster (9.2% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
AVNS vs HCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $246.2M |
| Net Profit | $-1.3M | $97.7M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 58.5% |
| Net Margin | -0.7% | 39.7% |
| Revenue YoY | 0.7% | 52.1% |
| Net Profit YoY | 99.7% | 3679.2% |
| EPS (diluted) | $-0.02 | $7.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $246.2M | ||
| Q3 25 | $177.8M | $216.3M | ||
| Q2 25 | $175.0M | $221.9M | ||
| Q1 25 | $167.5M | $216.4M | ||
| Q4 24 | $179.6M | $161.9M | ||
| Q3 24 | $170.4M | $175.3M | ||
| Q2 24 | $171.7M | $206.2M | ||
| Q1 24 | $166.1M | $206.6M |
| Q4 25 | $-1.3M | $97.7M | ||
| Q3 25 | $-1.4M | $65.5M | ||
| Q2 25 | $-76.8M | $66.2M | ||
| Q1 25 | $6.6M | $69.7M | ||
| Q4 24 | $-397.3M | $2.6M | ||
| Q3 24 | $4.3M | $5.7M | ||
| Q2 24 | $1.8M | $54.1M | ||
| Q1 24 | $-900.0K | $47.6M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 58.5% | ||
| Q3 25 | 0.1% | 41.9% | ||
| Q2 25 | -42.6% | 42.5% | ||
| Q1 25 | 6.1% | 46.4% | ||
| Q4 24 | -233.0% | 3.6% | ||
| Q3 24 | 7.0% | 8.0% | ||
| Q2 24 | 3.7% | 36.9% | ||
| Q1 24 | 2.4% | 37.5% |
| Q4 25 | -0.7% | 39.7% | ||
| Q3 25 | -0.8% | 30.3% | ||
| Q2 25 | -43.9% | 29.8% | ||
| Q1 25 | 3.9% | 32.2% | ||
| Q4 24 | -221.2% | 1.6% | ||
| Q3 24 | 2.5% | 3.2% | ||
| Q2 24 | 1.0% | 26.2% | ||
| Q1 24 | -0.5% | 23.0% |
| Q4 25 | $-0.02 | $7.29 | ||
| Q3 25 | $-0.03 | $4.90 | ||
| Q2 25 | $-1.66 | $5.18 | ||
| Q1 25 | $0.14 | $5.35 | ||
| Q4 24 | $-8.64 | $0.32 | ||
| Q3 24 | $0.09 | $0.52 | ||
| Q2 24 | $0.04 | $4.24 | ||
| Q1 24 | $-0.02 | $3.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $1.2B |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.0B |
| Total Assets | $1.1B | $2.5B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $1.2B | ||
| Q3 25 | $70.5M | $987.9M | ||
| Q2 25 | $90.3M | $947.2M | ||
| Q1 25 | $97.0M | $754.5M | ||
| Q4 24 | $107.7M | $532.5M | ||
| Q3 24 | $89.0M | $518.8M | ||
| Q2 24 | $92.2M | $445.8M | ||
| Q1 24 | $75.8M | $655.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $1.0B | ||
| Q3 25 | $778.0M | $821.8M | ||
| Q2 25 | $776.3M | $758.6M | ||
| Q1 25 | $839.4M | $522.7M | ||
| Q4 24 | $828.5M | $453.3M | ||
| Q3 24 | $1.2B | $455.3M | ||
| Q2 24 | $1.2B | $447.3M | ||
| Q1 24 | $1.2B | $395.7M |
| Q4 25 | $1.1B | $2.5B | ||
| Q3 25 | $1.1B | $2.3B | ||
| Q2 25 | $1.0B | $2.4B | ||
| Q1 25 | $1.1B | $2.3B | ||
| Q4 24 | $1.2B | $2.2B | ||
| Q3 24 | $1.7B | $2.0B | ||
| Q2 24 | $1.7B | $1.9B | ||
| Q1 24 | $1.7B | $1.8B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $444.4M |
| Free Cash FlowOCF − Capex | $21.3M | $440.8M |
| FCF MarginFCF / Revenue | 11.8% | 179.0% |
| Capex IntensityCapex / Revenue | 3.8% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 4.55× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $771.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $444.4M | ||
| Q3 25 | $14.0M | $26.7M | ||
| Q2 25 | $6.8M | $145.0M | ||
| Q1 25 | $25.7M | $162.0M | ||
| Q4 24 | $57.9M | $331.8M | ||
| Q3 24 | $23.0M | $104.1M | ||
| Q2 24 | $27.8M | $-29.0M | ||
| Q1 24 | $-8.0M | $182.0M |
| Q4 25 | $21.3M | $440.8M | ||
| Q3 25 | $7.0M | $25.9M | ||
| Q2 25 | $-4.2M | $144.5M | ||
| Q1 25 | $19.0M | $160.3M | ||
| Q4 24 | $53.1M | $327.8M | ||
| Q3 24 | $20.0M | $103.2M | ||
| Q2 24 | $21.9M | $-30.1M | ||
| Q1 24 | $-12.1M | $181.0M |
| Q4 25 | 11.8% | 179.0% | ||
| Q3 25 | 3.9% | 12.0% | ||
| Q2 25 | -2.4% | 65.1% | ||
| Q1 25 | 11.3% | 74.1% | ||
| Q4 24 | 29.6% | 202.5% | ||
| Q3 24 | 11.7% | 58.9% | ||
| Q2 24 | 12.8% | -14.6% | ||
| Q1 24 | -7.3% | 87.6% |
| Q4 25 | 3.8% | 1.5% | ||
| Q3 25 | 3.9% | 0.4% | ||
| Q2 25 | 6.3% | 0.2% | ||
| Q1 25 | 4.0% | 0.8% | ||
| Q4 24 | 2.7% | 2.5% | ||
| Q3 24 | 1.8% | 0.5% | ||
| Q2 24 | 3.4% | 0.5% | ||
| Q1 24 | 2.5% | 0.5% |
| Q4 25 | — | 4.55× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 2.19× | ||
| Q1 25 | 3.89× | 2.32× | ||
| Q4 24 | — | 128.41× | ||
| Q3 24 | 5.35× | 18.33× | ||
| Q2 24 | 15.44× | -0.54× | ||
| Q1 24 | — | 3.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
